IP Library Granted Patent US 8,989,859
Granted Patent B2
US 8,989,859 · App. 14/162,210 · Granted Mar 24, 2015

Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction

Inventors: Mark E. Deem (Mountain View, CA); Hanson Gifford, III (Woodside, CA)
Assignee: Medtronic Ardian Luxembourg S.a.r.l.
A61B18/1492A61N1/0412A61N1/327A61N1/36017A61N1/36021A61N1/36071A61N1/0551A61B18/1477A61N1/0456A61N1/05
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,989,859
App. No.
14/162,210
Granted
Mar 24, 2015
Kind
B2
Abstract

Methods and apparatus are provided, for selective destruction or temporary disruption of nerves and/or conduction pathways in a mammalian body for the treatment of pain and other disorders. Apparatus comprises catheters having electrodes for targeting and affecting nerve tissue at a cellular level to reversible and irreversible nerve portion and incapacitation.

Claims (11)

1. A non-invasive method for treating a disorder in a human patient, the method comprising:

delivering energy from an electrode external to the patient to target nerves running along an artery of the patient,

wherein the delivered energy is sufficient to disrupt nerve function of the target nerves at a cellular level.

2. The method of claim 1 wherein the electrode is configured to deliver ultrasonic energy.

3. The method of claim 1 wherein delivering energy from an electrode external to the patient comprises delivering energy from an electrode in physical contact with skin of the patient.

4. The method of claim 1 wherein delivering energy from an electrode external to the patient comprises delivering energy from more than one location external to the patient.

5. The method of claim 1 wherein the delivered energy is sufficient to result in the death of a cell.

6. The method of claim 1 wherein the delivered energy selectively disrupts certain cells and not others.

7. The method of claim 6 wherein the cells that are not disrupted comprise part of a wall of the adjacent artery.

8. The method of claim 1 wherein the delivered energy results in apoptosis of the target nerve cells.

9. The method of claim 1 wherein the delivered energy permeabilizes a cell membrane of the target nerve cells.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NUMBER: 12/162,210 PREVIOUSLY RECORDED ON REEL 034882 FRAME 0776. ASSIGNOR(S) HEREBY CONFIRMS THE 14/162,210. Recorded Feb 6, 2015
From: ARDIAN, INC.
To: MEDTRONIC ARDIAN LLC
Reel/Frame 034913/0886 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2015
From: DEEM, MARK E.; GIFFORD, HANSON
To: THE FOUNDRY, INC.
Reel/Frame 034876/0668 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2015
From: THE FOUNDRY, INC.
To: ARDIAN, INC.
Reel/Frame 034876/0719 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2015
From: MEDTRONIC ARDIAN LLC
To: MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L.
Reel/Frame 034876/0776 →
CHANGE OF NAME Recorded Feb 3, 2015
From: ARDIAN, INC.
To: MEDTRONIC ARDIAN LLC
Reel/Frame 034882/0776 →
Continuity (5)
Continuation 13930500 · Jun 28, 2013
Continuation 12567521 · Sep 25, 2009
Continuation 11459582 · Jul 24, 2006
Provisional Application 60701747 · Jul 22, 2005
Related Publication 20140200573A1 · Jul 17, 2014